Evidence map›Paper›PMID 38123744›Full record

ArticleMolecular imaging and biology2024

Development, Characterization, and Radiation Dosimetry Studies of

Joonyoung Kim, David J Donnelly, Tritin Tran, Adrienne Pena, Andrea Olga Shorts, Thomas V Petrone, Yunhui Zhang, Kenneth M Boy, Paul M Scola, Daniel J Tenney and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  6. PET imaging of PD-L1 with a small molecule radiotracer.European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 3 countries.

Joonyoung Kim *Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA. joonyoung.kim@bms.com.ORCID 0009-0007-7906-5710
David J Donnelly *Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Tritin TranBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Adrienne PenaBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Andrea Olga ShortsBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Thomas V PetroneBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Yunhui ZhangBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Kenneth M BoyBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Paul M ScolaBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Daniel J TenneyBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Michael A PossBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Matthew G SoarsBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Samuel J BonacorsiBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Erin L ColeBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Diederik J GrootendorstBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Patrick L ChowBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Nicholas A MeanwellBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Shuyan DuBristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, NJ, 08543, USA.
Bristol-Myers Squibb (United States) · USBristol-Myers Squibb (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn cancer immunotherapy, the blockade of the interaction between programmed death-1 and its ligand (PD-1:PD-L1) has proven to be one of the most promising strategies. However, as mechanisms of resistance to PD-1/PD-L1 inhibition include variability in tumor cell PD-L1 expression in addition to standard tumor biopsy PD-L1 immunohistochemistry (IHC), a comprehensive and quantitative approach for measuring PD-L1 expression is required. Herein, we report the development and characterization of an PROCEDURES:

resultsIn vitro autoradiography showed an 8:1 binding ratio in L2987(PD-L1 +) vs. HT-29 (PD-L1-) tumors, more than 90% of which could be blocked with 1 nM of BMS-986189. Ex vivo autoradiography showed that

conclusion

Indexed as

B7-H1 AntigenNeoplasmsAnimalsHumansMicePeptidesPositron-Emission TomographyProgrammed Cell Death 1 ReceptorRadiometryB7-H1 AntigenPeptidesProgrammed Cell Death 1 Receptor18F-labeled macrocyclic peptidePD-1:PD-L1 checkpoint inhibitorPreclinical PET imaging

Identifiers

PMID38123744
PMCPMC10973053
OpenAlexW4390013975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.